ANTIBODY FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND TYPE 2 (HIV 1 AND HIV 2) - ANVISA Registration 80142170076
Access comprehensive regulatory information for ANTIBODY FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND TYPE 2 (HIV 1 AND HIV 2) in Brazil's medical device market through Pure Global AI's free database. This Risk Class IV medical device is registered under ANVISA number 80142170076 and manufactured by Fundação Oswaldo Cruz - Instituto de Tecnologia em Imunobiológicos -. The registration is held by FUNDACAO OSWALDO CRUZ with validity until Jul 28, 2035.
This page provides complete technical specifications for this device, regulatory compliance details, 5 companies making the same product including WAMA PRODUTOS PARA LABORATORIO LTDA, Eco Diagnostica Ltda, and 5 recent registrations in the same technical category. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
80142170076
25351449915202446
33781055000135
Company Information
Dates and Status
Jul 28, 2025
28/07/2035
09/18/2025 19:00:01
ANTICORPO PARA VÍRUS DE IMUNODEFICIÊNCIA HUMANA TIPO 1 E TIPO 2 (HIV 1 E HIV 2)
Yumizen M HIV
HORIBA INSTRUMENTS BRASIL LTDA
10347320388
Sep 01, 2025
ANTICORPO PARA VÍRUS DE IMUNODEFICIÊNCIA HUMANA TIPO 1 E TIPO 2 (HIV 1 E HIV 2)
Teste Rápido Anti-HIV 1 e 2 Bahiafarma (Ouro Coloidal)
BEIJING HOTGEN BIOTECH CO., LTD
81285200024
Jun 16, 2025
ANTICORPO PARA VÍRUS DE IMUNODEFICIÊNCIA HUMANA TIPO 1 E TIPO 2 (HIV 1 E HIV 2)
Teste Rápido Anti-HIV 1 e 2 Bahiafarma (Ouro Coloidal)
Not specified
81285200024
Jun 16, 2025
ANTICORPO PARA VÍRUS DE IMUNODEFICIÊNCIA HUMANA TIPO 1 E TIPO 2 (HIV 1 E HIV 2)
HIV 1/2 Ab Combo ECO Teste
Eco Diagnostica Ltda
80954880227
May 05, 2025
ANTICORPO PARA VÍRUS DE IMUNODEFICIÊNCIA HUMANA TIPO 1 E TIPO 2 (HIV 1 E HIV 2)
HIV (1/2) Antibody Test Kit (Colloidal Gold)
Not specified
82444370173
Jan 27, 2025

